APA (7th ed.) Citation

Feuring-Buske, M., Kneba, M., Unterhalt, M., Engert, A., Gramatzki, M., Hiller, E., . . . Hiddemann, W. (2000). IDEC-C2B8 (Rituximab) anti-CD20 antibody treatment in relapsed advanced-stage follicular lymphomas: Results of a phase-II study of the German Low-Grade Lymphoma Study Group. Springer.

Chicago Style (17th ed.) Citation

Feuring-Buske, M., et al. IDEC-C2B8 (Rituximab) Anti-CD20 Antibody Treatment in Relapsed Advanced-stage Follicular Lymphomas: Results of a Phase-II Study of the German Low-Grade Lymphoma Study Group. Springer, 2000.

MLA (9th ed.) Citation

Feuring-Buske, M., et al. IDEC-C2B8 (Rituximab) Anti-CD20 Antibody Treatment in Relapsed Advanced-stage Follicular Lymphomas: Results of a Phase-II Study of the German Low-Grade Lymphoma Study Group. Springer, 2000.